Kura Oncology, Inc. is a biopharmaceutical company developing small molecule precision medicines for the treatment of cancer. Founded in 2014, the company operates a diversified pipeline focused on oncology and hematology, targeting cancer signaling pathways and unmet medical needs. Its approved product, ziftomenib, marketed as KOMZIFTI, is indicated for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation. The company is advancing ziftomenib in Phase 3 trials for newly diagnosed AML and in combination with imatinib for gastrointestinal stromal tumors. Kura Oncology is also evaluating KO-7246, a next-generation menin inhibitor, for diabetes and cardiometabolic disorders, and darlifarnib, a farnesyl transferase inhibitor, in combination with targeted therapies for solid tumors including renal cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The company utilizes translational research and companion diagnostics to identify patient populations likely to benefit from its therapies.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage kuraoncology.com
Sector Healthcare IR page fiercebiotech.com/biotech/fda-s-renewed-focus-oncology-dosing-spooks-investors-but-companies-say-they-were-ready
Tags
oncology, hematology, small molecules, precision medicine, menin inhibitors, farnesyl transferase inhibitors, acute myeloid leukemia, solid tumors, cardiometabolic disorders, KOMZIFTI, ziftomenib, KO-7246, darlifarnib
Press page kuraoncology.com/newsroom

Metrics

Valuation  
Market cap $ 684.76M
Market cap (USD) $ 684.76M
P/E -2.26
PEG —
P/BV 38.13
P/S 8.63
P/OCF -8.00
P/FCF -7.68
Dividend yield —
Turnover / mcap —
Returns  
ROE -94.8%
ROI -151.6%
ROIC -123.9%
Profit margin -412.9%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 54.7%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 90
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue 67.482M 53.883M — — — — — — — — — — — — — — — —
Net profit -278.666M -173.983M -152.631M -135.84M -130.466M -89.625M -63.14M -60.447M -35.434M -27.56M -22.625M -30.734K -28.611K -27.315K -27.04K -22.395K — —
Free cash flow -70.696M 133.845M -124.992M -110.688M -105.698M -72.001M — — — — -17.989M — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 10.39 8.71 14.38 12.41 14 32.66 13.75 14.04 15.3 5.9 8.4 — — — — — — —
Price performance 12m 0.19 -0.39 0.16 -0.11 -0.57 1.38 -0.02 -0.08 1.59 -0.3 — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — — 2.06M 8.8M
↳ YoY growth +327.4%
Borrowings, current (USD) — 1.53M — 250,000 3M — — — 2.61M 0.00
Borrowings, non-current (USD) 7.32M 5.57M 7.5M 7.25M 4.25M — 9.16M 9.33M 6.92M 9.71M
Lease liabilities (USD) — — 600,000 252,000 7.69M 6.88M 4.87M 7.87M 7.07M 10.7M
Cash and deposits (USD) 9.73M 11.4M 16.1M 26.1M 325M 90.7M 51.8M 37.3M 224M 149M
Right-of-use assets (USD) — — 600,000 234,000 6.3M 5.57M 3.84M 6.99M 5.8M 7.3M
Net debt (borrowings + leases - cash) (USD) -2.4M -4.34M -8.62M -18.4M -311M — -37.8M -20.1M -208M -129M
Cash flow detail
Operating cash flow (USD) -25.3M -28.4M -48.7M -54.8M -69.8M -105M -110M -125M 134M -64.1M
Purchases of property, plant and equipment (USD) — — — — -2.17M -1.15M -626,000 -168,000 -472,000 -6.64M
Change in receivables (cash effect) (USD) — — — — — — — 0.00 -2.06M -6.74M
Change in inventories (cash effect) (USD) — — — — — — — 0.00 0.00 -413,000
Change in payables (cash effect) (USD) — 3.05M 5.12M 856,000 5.68M -2.52M -802,000 10.3M 15.2M 4.5M
Interest paid (cash effect) (USD) -352,000 -627,000 -641,000 -430,000 -419,000 -784,000 -73,000 -1.06M -1.1M -998,000
Income taxes paid (cash effect) (USD) — — — — — — — — — -2.31M
Share-based compensation (USD) 2.09M 4.55M 8.65M 9.41M 12.8M 23.6M 26.3M 28.1M 33.9M 37.1M
Operating cash flow before change in receivables (USD) — — — — — — — -125M 136M -57.3M
Free cash flow (OCF - PPE - intangibles) (USD) — — — — -72M -106M -111M -125M 134M -70.7M
Income detail
Research and development expense (USD) — 26.4M 46.8M 47.8M 60.4M 84.7M 92.8M 115M 170M 251M
↳ 5y CAGR +28.6% +19.8% +28.9% +33.0%
Total comprehensive income (USD) -27.5M -35.5M -60.5M -62.7M -89.9M -132M -142M -146M -172M -278M
Comprehensive income to owners (USD) -27.5M -35.5M -60.5M -62.7M -89.9M -132M -142M -146M -172M -278M
Reported Mar 14, 2017 Feb 25, 2020 Feb 25, 2020 Feb 25, 2020 Feb 24, 2021 Feb 24, 2022 Feb 23, 2023 Mar 5, 2026 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– KOMZIFTI®(ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% –

– KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market –

– Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML –

– FDA alignment for approximately 40-patient monotherapy registrational study of darlifarnib in HRAS-mutated salivary gland cancer; study initiation targeted for 1H 2027 –

– Darlifarnib combination studies in renal cell and pancreatic cancers expected to reach key development milestones in 2027 –

– Strong financial position, supported by $492.1 million in cash, cash equivalents and short-term investments, anticipated Kyowa Kirin collaboration payments and up to $300 million additional financing capacity from Oberland Capital –

– Management to host webcast and conference call today at 4:30 p.m. ET / 1:30 p.m. PT –

SAN DIEGO, November 10, 2026 – Kura Oncology, Inc.

11-06-2026

PDF Version

SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 55,500 shares of common stock to three (3) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $9.79 per share, the closing price of the Company’s common stock on November 2, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Kura Contact

Investors and Media: Greg Mann 858-987-4046 [email protected]

Primary Logo

Footer Links - Top

Footer Links - Investors New

Footer Links - Careers

Footer Links - News & Media

01 Footer Links - Contact

Kura Oncology, Inc. 4930 Directors Place, Suite 500 San Diego, CA 92121 (858) 500-8800

Kura Oncology, Inc. 2 Seaport Lane, Suite 8A Boston, MA 02210 (617) 588-3755

© 2026 Kura Oncology, Inc. All Rights Reserved | Terms of Use | Privacy Policy | Cookie Policy | Consumer Health Data | Your Privacy Choices

Scroll to top

Company Logo

Privacy Preference Center

When you visit our website, we and third parties may store or retrieve information on your browser, such as information about your device or your actions on the website, mostly in the form of cookies. You may choose not to allow some types of cookies. Select the different category headings to learn more and change our default settings, and then select “Confirm My Choices” to save these settings.

Accept Non-Essential Cookies

Manage Consent Preferences

Essential Cookies

Always Active

These cookies are necessary for the website to operate. They are usually set for security or fraud detection purposes or in response to actions you take, such as to save your privacy preferences. You may set your browser to block or alert you about these cookies, but this could disrupt your experience on the website.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic to our website so we can measure and improve how our website performs. They help us to know things like which pages are the most and least popular and how visitors move around our website.

Targeted Advertising Cookies

Targeted Advertising Cookies

These cookies may be set through our websites by us or our advertising partners. They collect information about your visits and activity, such as the pages you view, and use unique identifiers to recognize your browser or device. We and our partners may use this information to understand your interests and show you more relevant ads, including ads about our company and products, on websites and services we do not operate. These cookies also help us measure the effectiveness of our advertising efforts.

Functional Cookies

Functional Cookies

These cookies enable the website to provide enhanced functionality and power certain optional features of our website. They may be set by us or by third party providers whose services we use on our website. If you do not allow these cookies, then the features they power will not function properly.

Cookie List

Clear

  • checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject Non-Essential Cookies

Powered by Onetrust

11-04-2026

PDF Version

– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –

– Longer-term Phase 1b data for ziftomenib plus venetoclax and azacitidine in frontline AML support the ongoing Phase 3 KOMET-017 registrational study –

– Exploratory analysis to evaluate ziftomenib clinical activity beyond NPM1-mutated and KMT2A-rearranged subtypes –

– A total of four oral presentations and four posters to highlight the expanding potential of menin inhibition with ziftomenib across AML treatment settings and combinations –

– Investor webcast on December 15, 2026, at 8:30 a.m. ET / 5:30 a.m. PT –

SAN DIEGO and TOKYO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd (TSE: 4151) today announced that eight abstracts related to ziftomenib, including four oral presentations and four posters, have been accepted for presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12-15 in New Orleans. Kura and Kyowa Kirin are working together under a strategic collaboration and license agreement to develop and commercialize ziftomenib for the treatment of acute myeloid leukemia (AML) worldwide.

The presentations will include the first clinical results for ziftomenib in combination with the FLT3 inhibitors quizartinib and gilteritinib, longer-term frontline data for ziftomenib plus venetoclax and azacitidine, and an exploratory analysis of ziftomenib activity in molecularly defined AML subtypes beyond NPM1-mutated and KMT2A-rearranged disease.

“Our strategy is to establish ziftomenib as a preferred menin inhibitor for combination treatment, supported by clinical evidence across complementary therapeutic approaches,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “Our first clinical results with quizartinib and gilteritinib extend this strategy into FLT3 inhibitor combinations. Together with longer-term venetoclax and azacitidine results and studies of additional combinations, these presentations will help define ziftomenib’s potential as a backbone therapy from initial diagnosis through relapsed or refractory disease.”

FLT3 mutations occur in nearly one third of patients with AML and approximately one half of those with an NPM1 mutation. This overlap makes NPM1/FLT3 co-mutated AML an important population for ziftomenib combination development.

Two oral presentations will report preliminary safety and clinical activity findings from ziftomenib combinations with FLT3 inhibitors:

  • KOMET-007: Ziftomenib plus quizartinib and intensive chemotherapy (7+3) in newly diagnosed NPM1/FLT3-ITD co-mutated AML

  • KOMET-008: Ziftomenib plus gilteritinib in relapsed or refractory (R/R) NPM1/FLT3 co-mutated AML

A poster presentation from KOMET-007 will provide longer-term follow-up on response durability, overall survival, and safety with ziftomenib plus venetoclax and azacitidine in patients with newly diagnosed NPM1-mutated AML who are ineligible for intensive chemotherapy. These findings support the ongoing global, randomized Phase 3 KOMET-017 registrational study evaluating this combination.

An exploratory analysis from KOMET-001 will describe clinical activity with ziftomenib monotherapy in patients with R/R AML without NPM1 mutations or KMT2A rearrangements whose disease harbors other genomic alterations associated with MEIS1 expression. The findings support further investigation of ziftomenib in additional molecularly defined AML populations.

Two additional oral presentations will feature ziftomenib. The first will report initial results from the PedAL Phase 1 ITCC-101/APAL2020K trial sponsored by Blood Cancer United and Princess Maxima Center evaluating ziftomenib with fludarabine and cytarabine in pediatric R/R acute leukemia. The second will present preclinical findings from additional subsets of menin-associated leukemias.

All eight abstracts related to ziftomenib, including those from investigator-sponsored trials, are available on the ASH website.

Select 2026 ASH Presentation Details

| Abstract Title | Abstract Number | Presentation Details |

| Ziftomenib combined with gilteritinib for relapsed/refractoryNPM1andFLT3co-mutated acute myeloid leukemia (AML): First results from the KOMET-008 phase 1 study | Oral Presentation #66 | Session 617 December 12 10:45 a.m. CST Great Hall AD |

| Ziftomenib combined with intensive induction (7+3) and quizartinib for newly diagnosedNPM1-m andFLT3-ITD+ acute myeloid leukemia (AML): Preliminary results from KOMET-007 | Oral Presentation #902 | Session 617 December 14 3:00 p.m. CST Great Hall BC |

| Ziftomenib combined with venetoclax/azacitidine in newly diagnosedNPM1-m acute myeloid leukemia (AML): Long-term results from KOMET-007 | Poster Presentation #5192 | Session 617 December 14 6:00-8:00 p.m. CST Hall F |

| Clinical activity of ziftomenib extends beyondNPM1-mutated andKMT2A-rearranged acute myeloid leukemia (AML) intoMEIS1-associated genomic subtypes | Poster Presentation #5190 | Session 617 December 14 6:00-8:00 p.m. CST Hall F |

| Ziftomenib combined with fludarabine and cytarabine in pediatric relapsed/refractory acute leukemia withKMT2Arearrangements,NUP98rearrangements, orNPM1mutations: First results of the phase 1 ITCC-101/APAL2020K trial (NCT06376162) | Oral Presentation #666 | Session 616 December 13 5:45 p.m. CST Hall B |

| SETBP1-mutant leukemias depend on MENIN-associated KMT2A chromatin complexes to maintain leukemogenic transcriptional programs | Oral Presentation #101 | Session 636 December 12 10:30 a.m. CST Hall C |

Conference Call and Webcast

Kura will host a webcast and conference call at 8:30 a.m. ET / 5:30 a.m. PT on December 15, 2026, featuring Kura management, Eunice Wang, M.D., Chief of Leukemia Service and Professor of Oncology at Roswell Park Comprehensive Cancer Center, and Amer Zeidan, M.B.B.S., M.H.S., Chief, Division of Hematologic Malignancies and Professor of Medicine at Yale School of Medicine. A live webcast and archived replay of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

About Kyowa Kirin

Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin’s values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.

About KOMZIFTI**®****(ziftomenib)** KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.

Ziftomenib is in development for the treatment of frontline and R/R AML harboring NPM1 mutations, KMT2A translocations and FLT3 mutations, with the potential to be combined with approved therapies and benefit a broad spectrum of patients.

IMPORTANT SAFETY INFORMATION FOR KOMZIFTI FROM THE U.S. PRESCRIBING INFORMATION

Boxed WARNING: DIFFERENTIATION SYNDROME

Differentiation syndrome, which can be fatal, has occurred with KOMZIFTI. Signs and symptoms may include fever, joint pain, hypotension, hypoxia, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, pulmonary infiltrates, acute kidney injury, and rashes. If differentiation syndrome is suspected, interrupt KOMZIFTI, and initiate oral or intravenous corticosteroids with hemodynamic and laboratory monitoring until symptom resolution; resume KOMZIFTI upon symptom improvement.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome

KOMZIFTI can cause fatal or life-threatening differentiation syndrome (DS). DS is associated with rapid proliferation and differentiation of myeloid cells. Symptoms of DS, including those seen in patients treated with KOMZIFTI, may include fever, hypoxia, joint pain, hypotension, dyspnea, rapid weight gain or peripheral edema, pleural or pericardial effusions, acute kidney injury, and rashes.

In the clinical trial, DS occurred in 29 (26%) of 112 patients with R/R AML with an NPM1 mutation who were treated with KOMZIFTI at the recommended dosage. DS was Grade 3 in 13% and fatal in two patients. In broader evaluation of all patients with any genetic form of AML treated with KOMZIFTI monotherapy in clinical trials, DS occurred in 25% of patients. Four fatal cases of DS occurred out of 39 patients with KMT2A-rearranged AML treated with KOMZIFTI. KOMZIFTI is not approved for use in patients with KMT2A-rearranged AML.

In the 112 patients with an NPM1 mutation, DS was observed with and without concomitant hyperleukocytosis, in as early as 3 days and up to 46 days after KOMZIFTI initiation. The median time to onset was 15 days. Two patients experienced more than one DS event. Treatment was interrupted and resumed in 15 (13%) patients, while it was permanently discontinued in 2 (2%) patients.

Prior to starting treatment with KOMZIFTI, reduce the WBC counts to less than 25 x 10⁹/L. If DS is suspected, interrupt KOMZIFTI, initiate oral or intravenous corticosteroids (e.g., dexamethasone 10 mg every 12 hours) for a minimum of 3 days with hemodynamic and laboratory monitoring. Resume treatment with KOMZIFTI at the same dose level when signs and symptoms improve and are Grade 2 or lower. Taper corticosteroids over a minimum of 3 days after adequate control or resolution of symptoms. Symptoms of DS may recur with premature discontinuation of corticosteroid treatment.

QTc Interval Prolongation

KOMZIFTI can cause QTc interval prolongation. In the clinical trial, QTc interval prolongation was reported as an adverse reaction in 12% of 112 patients treated with KOMZIFTI at the recommended dosage for R/R AML with an NPM1 mutation. QTc interval prolongation was Grade 3 in 8% of patients. The heart-rate corrected QT interval (using Fridericia’s method) (QTcF) was greater than 500 msec in 9% of patients, and the increase from baseline QTcF was greater than 60 msec in 12% of patients. KOMZIFTI dose reduction was required for 1% of patients due to QTc interval prolongation. QTc prolongation occurred in 14% of the 42 patients less than 65 years of age and in 10% of the 70 patients 65 years of age or older.

Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to treatment with KOMZIFTI. Perform an ECG prior to initiation of treatment with KOMZIFTI, and do not initiate KOMZIFTI in patients with QTcF > 480 msec. Perform an ECG at least once weekly for the first four weeks on treatment, and at least monthly thereafter. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms (Grade 3). In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use of KOMZIFTI with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation, result in a greater increase in the QTc interval and adverse reactions associated with QTc interval prolongation, including Torsades de Pointes, other serious arrhythmias, and sudden death.

Embryo-Fetal Toxicity

Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with KOMZIFTI and for 3 months after the last dose.

ADVERSE REACTIONS

Fatal adverse reactions occurred in 4 (4%) patients who received KOMZIFTI, including 2 with differentiation syndrome, 1 with infection, and 1 with sudden death. Serious adverse reactions were reported in 79% of patients who received KOMZIFTI. Serious adverse reactions occurring in ≥ 5% of patients included infection without an identified pathogen (29%), febrile neutropenia (18%), bacterial infection (16%), differentiation syndrome (16%), and dyspnea (6%).

Dosage interruption of KOMZIFTI due to an adverse reaction occurred in 54% of patients. Adverse reactions that required dose interruption in ≥ 2% of patients included infection without an identified pathogen (15%), differentiation syndrome (13%), febrile neutropenia (5%), pyrexia (4%), electrocardiogram QT prolonged (4%), leukocytosis (4%), bacterial infection (3%), cardiac failure (2%), cholecystitis (2%), diarrhea (2%), pruritus (2%), and thrombosis (2%). Dose reduction of KOMZIFTI due to an adverse reaction occurred in 4% of patients. Permanent discontinuation of KOMZIFTI due to an adverse reaction occurred in 21% of patients. Adverse reactions that required permanent discontinuation of KOMZIFTI in ≥ 2% of patients were infection without an identified pathogen (8%), bacterial infection (4%), cardiac arrest (2%), and differentiation syndrome (2%).

Most common (≥ 20%) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased (53%), infection without an identified pathogen (52%), potassium decreased (52%), albumin decreased (51%), alanine aminotransferase increased (50%), sodium decreased (49%), creatinine increased (45%), alkaline phosphatase increased (41%), hemorrhage (38%), diarrhea (36%), nausea (35%), fatigue (34%), edema (30%), bacterial infection (28%), musculoskeletal pain (28%), bilirubin increased (27%), potassium increased (26%), differentiation syndrome (26%), pruritus (23%), febrile neutropenia (22%), and transaminases increased (21%).

DRUG INTERACTIONS

Drug interactions may occur when KOMZIFTI is concomitantly used with:

  • Strong or Moderate CYP3A4 Inhibitors: Monitor patients more frequently for KOMZIFTI-associated adverse reactions.

  • Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of KOMZIFTI.

  • Gastric Acid Reducing Agents: Avoid concomitant use of KOMZIFTI with proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs), or locally acting antacids. If concomitant use with H2RAs or locally acting antacids cannot be avoided, modify KOMZIFTI administration time.

  • Take KOMZIFTI 2 hours before or 10 hours after administration of an H2 receptor antagonist.

  • Take KOMZIFTI 2 hours before or 2 hours after administration of a locally acting antacid.

  • Drugs that Prolong the QTc Interval: Avoid concomitant use of KOMZIFTI. If concomitant use cannot be avoided, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt KOMZIFTI if the QTc interval is > 500 ms or the change from baseline is > 60 ms.

USE IN SPECIFIC POPULATIONS

**Pregnancy:**Based on findings in animals and its mechanism of action, KOMZIFTI can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to starting KOMZIFTI.

Lactation: Because of the potential for adverse reactions in the breastfed child, advise women not to breastfeed during treatment with KOMZIFTI and for 2 weeks after the last dose.

Infertility: Based on findings in animals, KOMZIFTI may impair fertility in females and males of reproductive potential.

Please see full Prescribing Information, including Boxed WARNINGfor additional details.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Kura’s plans and objectives for the clinical development of ziftomenib, including combination regimens and the ongoing Phase 3 KOMET-017 study; ziftomenib’s potential to become a preferred menin inhibitor for combination treatment and a foundational component of AML treatment from initial diagnosis through relapsed or refractory disease; the potential therapeutic benefits of ziftomenib in combination with other agents; the potential for ziftomenib to address additional molecularly defined AML populations beyond NPM1-mutated and KMT2A-rearranged disease; and the development and commercialization of ziftomenib under Kura’s collaboration agreement with Kyowa Kirin. Factors that may cause actual results to differ materially include the risk that preliminary, interim or exploratory clinical findings may change as additional patients are enrolled or longer-term follow-up becomes available; the risk that results from early-stage studies may not predict results in later-stage trials; the risk that additional studies may not confirm the safety, efficacy or durability of response suggested by earlier findings; risks associated with initiating, enrolling, conducting and completing clinical trials; unexpected adverse events or other safety findings; the risk that regulatory authorities may not permit planned studies to proceed or approve additional indications or combination regimens; the availability of sufficient funding to support development activities; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Prompts

Kura Oncology, Inc. (ticker KURA), listed in United States.

Company History

Date Change Detail
Mar 12, 2015 Renamed ZETA ACQUISITION CORP III → KURA ONCOLOGY, INC.

ETFs Holding Kura Oncology, Inc.

ETF Weight in ETF Shares Market value As of
CANC 1.03% 171,385 $ 2.168M Aug 31, 2026
FSEG 0.11% 556 $ 6,099.32 Jun 30, 2026
FSEV 0.10% 592 $ 6,494.24 Jun 30, 2026
FESM 0.05% 263,839 $ 2.894M Jun 30, 2026
RESM 0.03% 100 $ 1,097.00 Jun 30, 2026
MSSM 0.01% 5,377 $ 68.019K Aug 31, 2026
DFAC 0.00% 232,585 $ 1.728M Nov 12, 2026
DFUS 0.00% 14,853 $ 110.358K Nov 12, 2026
DFAU 0.00% 4,349 $ 32.313K Nov 12, 2026
DCOR 0.00% 11,798 $ 87.659K Nov 12, 2026
AVSC 0.00% 861 $ 6,104.49 Nov 16, 2026